177 related articles for article (PubMed ID: 31801830)
1. Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease.
Cavedo E; Lista S; Houot M; Vergallo A; Grothe MJ; Teipel S; Zetterberg H; Blennow K; Habert MO; Potier MC; Dubois B; Hampel H; ; Alzheimer Precision Medicine Initiative
Neurology; 2020 Jan; 94(1):e30-e41. PubMed ID: 31801830
[TBL] [Abstract][Full Text] [Related]
2. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
[TBL] [Abstract][Full Text] [Related]
3. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
4. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
5. Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease.
Teipel S; Heinsen H; Amaro E; Grinberg LT; Krause B; Grothe M;
Neurobiol Aging; 2014 Mar; 35(3):482-91. PubMed ID: 24176625
[TBL] [Abstract][Full Text] [Related]
6. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
Rauchmann BS; Schneider-Axmann T; Perneczky R;
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
8. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease.
Illán-Gala I; Lleo A; Karydas A; Staffaroni AM; Zetterberg H; Sivasankaran R; Grinberg LT; Spina S; Kramer JH; Ramos EM; Coppola G; La Joie R; Rabinovici GD; Perry DC; Gorno-Tempini ML; Seeley WW; Miller BL; Rosen HJ; Blennow K; Boxer AL; Rojas JC
Neurology; 2021 Feb; 96(5):e671-e683. PubMed ID: 33199433
[TBL] [Abstract][Full Text] [Related]
9. Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study.
Baldacci F; Lista S; Manca ML; Chiesa PA; Cavedo E; Lemercier P; Zetterberg H; Blennow K; Habert MO; Potier MC; Dubois B; Vergallo A; Hampel H; ;
Alzheimers Res Ther; 2020 Nov; 12(1):147. PubMed ID: 33183357
[TBL] [Abstract][Full Text] [Related]
10. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
[TBL] [Abstract][Full Text] [Related]
11. Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid-β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints.
Chiesa PA; Cavedo E; Grothe MJ; Houot M; Teipel SJ; Potier MC; Habert MO; Lista S; Dubois B; Hampel H;
Radiology; 2019 Jan; 290(1):167-176. PubMed ID: 30351255
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
13. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
14. Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants.
Chatterjee P; Goozee K; Sohrabi HR; Shen K; Shah T; Asih PR; Dave P; ManYan C; Taddei K; Chung R; Zetterberg H; Blennow K; Martins RN
J Alzheimers Dis; 2018; 63(2):479-487. PubMed ID: 29630554
[TBL] [Abstract][Full Text] [Related]
15. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
[TBL] [Abstract][Full Text] [Related]
16. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
Palmqvist S; Tideman P; Cullen N; Zetterberg H; Blennow K; ; Dage JL; Stomrud E; Janelidze S; Mattsson-Carlgren N; Hansson O
Nat Med; 2021 Jun; 27(6):1034-1042. PubMed ID: 34031605
[TBL] [Abstract][Full Text] [Related]
17. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
Pereira JB; Westman E; Hansson O;
Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
[TBL] [Abstract][Full Text] [Related]
18. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
Brickman AM; Manly JJ; Honig LS; Sanchez D; Reyes-Dumeyer D; Lantigua RA; Lao PJ; Stern Y; Vonsattel JP; Teich AF; Airey DC; Proctor NK; Dage JL; Mayeux R
Alzheimers Dement; 2021 Aug; 17(8):1353-1364. PubMed ID: 33580742
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
20. Utility of Plasma Neurofilament Light in the 1Florida Alzheimer's Disease Research Center (ADRC).
Barker W; Quinonez C; Greig MT; Behar R; Chirinos C; Rodriguez RA; Rosselli M; Rodriguez MJ; Cid RC; Rundek T; McFarland K; Hanson K; Smith G; DeKosky S; Vaillancourt D; Adjouadi M; Marsiske M; Ertekin-Taner N; Golde T; Loewenstein DA; Duara R
J Alzheimers Dis; 2021; 79(1):59-70. PubMed ID: 33216030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
